Showing 35,225 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

PrEP science

New data from PrEP study shed light on adherence, bone mineral loss and resistance

News
2 March 2011
New & experimental HIV treatments

Tobira reports on PK, safety, of new CCR5 inhibitor cenicriviroc

Editor's pick
Bioportfolio
2 March 2011
Side effects

Abacavir not linked to increased risk of heart attack, reports US FDA

News
2 March 2011
Ageing & HIV

Decreased limb muscle and increased abdominal fat linked to higher mortality in people with HIV

News
2 March 2011
New & experimental HIV treatments

Recombinant Interleukin-7 (CYT107) Expands CD4 T-Cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-Responder Patients

Editor's pick
HIV / AIDS News From Medical News Today
2 March 2011
How HIV works

NIH-funded study shows early brain effects of HIV in mouse model

Editor's pick
EurekAlert
2 March 2011
Adherence

Intensive adherence counseling with HIV treatment improves patient outcomes

Editor's pick
Eurekalert HIV
1 March 2011
Neurological & cognitive problems

Previous Syphilis Infection Might Cause Poorer Brain Function for People With HIV

Editor's pick
AIDSmeds.com
1 March 2011
Treatment for women

Studies in Post-Menopausal Women Reveal Potentially Higher Biological HIV Risk, as Well as Possible Tenofovir Concerns

Editor's pick
The BodyPro
1 March 2011
Starting treatment

3-year results on Merck’s ISENTRESS® (raltegravir): sustained viral load suppression and tolerability

Editor's pick
Business Week
1 March 2011
Finance & funding

Winners and losers in the UK aid review

Editor's pick
The Guardian
1 March 2011
HIV treatment

Glaxo Seeks $1.5 Billion in AIDS Drug Trial Against Abbott

Editor's pick
Bloomberg
1 March 2011
Viral load

Treatment monitoring: no clear benefit to adding viral load to CD4 or clinical symptoms in Thailand and Africa

News
1 March 2011
Finance & funding

UK aid budget refocuses 'on areas of greatest need'

Editor's pick
The Guardian
1 March 2011
New & experimental HIV treatments

Attachment inhibitor BMS-663068 potent and well-tolerated in early study

News
1 March 2011
Sexual transmission

Safer sex in the treatment era

News
1 March 2011
The search for an HIV prevention vaccine

What about a vaccine?

News
1 March 2011

Choose your runner

News
1 March 2011
New & experimental HIV treatments

Towards a cure for all: How we might do it

News
1 March 2011
Ethnic & cultural minorities

Risk of Virologic Failure 40 Percent Higher Among Blacks vs. Whites

Editor's pick
Kaiser Daily Global Health Policy Report
1 March 2011
Treatment outcomes & life expectancy

Risk of Virologic Failure 40 Percent Higher Among Blacks vs. Whites

Editor's pick
AIDSMeds
1 March 2011
New & experimental HIV treatments

Zinc finger gene therapy produces HIV-resistant CD4 T-cells

News
1 March 2011
Vaginal rings & topical PrEP

Vaginal microbicides may not be safe for rectal use: gels being reformulated

News
1 March 2011
Vaginal rings & topical PrEP

One dose of raltegravir gel three hours after sex might prevent HIV infection

News
1 March 2011